Pramlintide
The first amylin analog — native amylin with its self-aggregation edited out.
Identity
- Class
- Amylin analog (synthetic 37 aa peptide)
- Source
- Synthetic analog of human amylin
- Receptor
- Amylin receptors (calcitonin receptor + RAMP)
Mechanism
Pramlintide is a synthetic amylin analog carrying three proline substitutions — borrowed from non-aggregating rodent amylin — that prevent the fibril formation which makes native human amylin undruggable. At amylin receptors it reproduces amylin's biology: slowing gastric emptying, suppressing post-meal glucagon, and promoting satiety. It is approved as an adjunct to mealtime insulin, the two hormones' natural partnership rebuilt as a drug.
Reference notes
- The proline substitutions solve amylin's self-aggregation problem — the core engineering that made a stable amylin drug possible.
- Approved as an adjunct to mealtime insulin in type 1 and type 2 diabetes.
- Complements insulin rather than replacing it — amylin and insulin are co-secreted natively.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Pramlintide and the treatment of diabetes: a review of the data since its introduction · Expert opinion on pharmacotherapy, 2011 · PMID 21564002
- 2.Pramlintide · , 2006 · PMID 30000033